Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23228443 | 0.84 | PLAU (0.43) | LMNASMN1; SMN2NPC1RAB9AUHRF1 | |
| SCHEMBL31541865 | 0.82 | KDM4E (0.41) | LMNASMN1; SMN2NPC1RAB9AUHRF1 | |
| SCHEMBL28758402 | 0.82 | KDM4E (0.41) | LMNASMN1; SMN2NPC1RAB9AUHRF1 | |
| SCHEMBL21241778 | 0.81 | LMNA (0.42) | LMNASMN1; SMN2NPC1RAB9AUHRF1 | |
| SCHEMBL20890612 | 0.81 | NPC1 (0.42) | LMNASMN1; SMN2NPC1RAB9AUHRF1 | |
| SCHEMBL134563 | 0.80 | LMNA (0.38) | LMNASMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL12988886 | 0.80 | LMNA (0.38) | LMNASMN1; SMN2NPC1RAB9AKDM4E | |
| Hydrochloric Acid SCHEMBL31292377 | 0.79 | PRKCI (0.38) | LMNASMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL18855007 | 0.78 | CNR2 (0.43) | LMNASMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL129055 | 0.76 | UHRF1 (0.48) | LMNASMN1; SMN2NPC1RAB9AUHRF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2681192-B1 | SYNTHESIS OF 2-CARBOXAMIDE CYCLOAMINO UREA DERIVATIVES | NOVARTIS AG (CH) | 2017-12-27 | — | — | EP | disclosed |
| US-20170355677-A1 | SYNTHESIS OF 2-CARBOXAMIDE CYCLOAMINO UREA DERIVATIVES | NOVARTIS AG (CH) | 2017-12-14 | — | — | US | disclosed |
| US-20170355677-A1 | SYNTHESIS OF 2-CARBOXAMIDE CYCLOAMINO UREA DERIVATIVES | NOVARTIS AG (CH) | 2017-12-14 | — | — | US | disclosed |
| US-9776966-B2 | Synthesis of 2-carboxamide cycloamino urea derivatives | NOVARTIS AG (CH) | 2017-10-03 | — | — | US | disclosed |
| US-9776966-B2 | Synthesis of 2-carboxamide cycloamino urea derivatives | NOVARTIS AG (CH) | 2017-10-03 | — | — | US | disclosed |
| US-20170240509-A1 | Synthesis of 2-carboxamide cycloamino urea derivatives | NOVARTIS AG (CH) | 2017-08-24 | — | — | US | disclosed |
| US-20170240509-A1 | Synthesis of 2-carboxamide cycloamino urea derivatives | NOVARTIS AG (CH) | 2017-08-24 | — | — | US | disclosed |
| US-9650373-B2 | Synthesis of 2-carboxamide cycloamino urea derivatives | NOVARTIS AG (CH) | 2017-05-16 | — | — | US | disclosed |
| US-9650373-B2 | Synthesis of 2-carboxamide cycloamino urea derivatives | NOVARTIS AG (CH) | 2017-05-16 | — | — | US | disclosed |
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| CN-101374844-A | Pyrrolopyridazinone compound | UBE INDUSTRIES (JP) | 2009-02-25 | — | — | CN | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355677-A1 | SYNTHESIS OF 2-CARBOXAMIDE CYCLOAMINO UREA DERIVATIVES | CPS1, UCK2, UMPS | LMNA 3388/4885SMN1; SMN2 3478/4885NPC1 3793/4885 |
| US-20170240509-A1 | Synthesis of 2-carboxamide cycloamino urea derivatives | CPS1, UCK2, UMPS | LMNA 3388/4885SMN1; SMN2 3478/4885NPC1 3793/4885 |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | LMNA 1679/4885SMN1; SMN2 4613/4885NPC1 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.